Sentinel Oncology Appoints John Dixon To Board Of Directors
Sentinel Oncology is pleased to announce the appointment of Dr. John Dixon to the board of Directors. Dr. Dixon, recently retired from Astra Zeneca, brings many years of expertise in the pharmaceutical industry and his appointment to the board is after serving on the Sentinel Oncology scientific advisory board for the past 18 months.
Stuart Travers, of Sentinel Oncology, said, “I am extremely pleased that John has agreed to join our board as his wealth of experience in the industry will add to the existing skills present.”
John Dixon has 36 years experience in Pharmaceutical Research & Development. He has been associated with and responsible for research projects into Respiratory, Inflammation, Cardiovascular and Gastrointestinal diseases. He is the inventor of one marketed cardiovascular drug and of several other compounds that reached advanced stages in Clinical Development.
John was Head of Medicinal Chemistry for 20 years at Fisons and Vice President of Preclinical R&D in Astra Charnwood for 4 years. For the last 8 years he has been Vice President of Drug Discovery at AstraZeneca R&D Charnwood with responsibility for 400 scientists working on Respiratory and Inflammation. His role has extended from Research into Drug Development involving several international locations within the company. He is a Fellow of the Royal Society of Chemistry and a Member of the American Chemical Society and has served on several professional and academic advisory committees. Recently he was awarded an honorary D.Sc. from the University of Loughborough. John is now an independent consultant in Drug Discovery involved in many organisations, academic, industrial and charitable in 6 different countries.
Commenting on the appointment, John said “Large organisations gave me an excellent opportunity to learn about important components of modern drug discovery with many projects in many therapy areas. It is now a real pleasure to be involved in smaller organisations such as Sentinel where focus and rapid decision making is normal. In Sentinel Oncology everyone is closely associated with the company objectives and can easily see the value of their contribution. I look forward to successful association with Sentinel Oncology.”
Sentinel Oncology is a small molecule discovery company focused on developing new and more effective treatments for cancer. Sentinel Oncology has built a pipeline of small molecules designed to target hallmarks of solid tumours. In particular Sentinel is developing small molecule inhibitors that are activated selectively under tumour Hypoxia (the low oxygen environment found in all solid tumours). The Sentinel Oncology vision is to successfully develop drugs in oncology that are void of the systemic toxicities often associated with chemotherapeutics.
